The headline number from retatrutide's newest phase 3 readout is big. The asterisk beside it is the part worth understanding. In July, Eli Lilly reported topline results from TRIUMPH-3, the trial that tested its triple-agonist in adults living with obesity and established cardiovascular disease — the group most trials of this kind quietly avoid. The weight loss landed. What the readout did not do is prove the drug prevents heart attacks and strokes, and that distinction matters more than any single percentage.

Here's what the retatrutide phase 3 TRIUMPH data actually says, and what it deliberately doesn't.

What TRIUMPH-3 Tested — and What It Didn't

TRIUMPH is not one trial. The programme consists of four phase 3, multicentre, randomised, double-blind studies of weekly subcutaneous retatrutide versus placebo, alongside diet and physical activity, in over 5,800 participants — two weight-management basket trials (TRIUMPH-1 and TRIUMPH-2) with obstructive sleep apnoea and/or osteoarthritis protocols nested inside them, one weight-management trial in a population with cardiovascular disease (TRIUMPH-3), and a stand-alone osteoarthritis trial (TRIUMPH-4).

That one line explains everything about how to read the new data. The primary endpoint for the weight-management trials is percent change in body weight — not major adverse cardiovascular events. TRIUMPH-3 recruited people with heart disease, but it was designed to answer how much weight does retatrutide take off in this population, not does retatrutide reduce cardiovascular events.

So when reporting on the July readout noted that patients on the 12 mg dose reached 22.6% weight loss while the impact on reducing cardiovascular risk was less clear, that isn't a failure. It's a trial doing the job it was designed for, and no more. A cardiovascular outcomes trial is a different, longer, event-driven animal.

The Numbers Lilly Reported

Lilly announced positive topline results from TRIUMPH-2 and TRIUMPH-3 on 23 July 2026, saying both met their primary endpoint and delivered substantial weight loss in adults with obesity and some of its most serious complications — type 2 diabetes and established cardiovascular disease — and that it plans to submit a Biologics License Application for retatrutide to the FDA in Q1 2027.

On the efficacy side, patients in TRIUMPH-2 receiving 12 mg saw 20.8% weight loss at 80 weeks, compared with 3.2% in the placebo group. Set that against the roughly 28.3% average reduction reported in TRIUMPH-1 at 12 mg over 80 weeks, and a consistent pattern across the programme comes into view: the harder the underlying metabolic burden, the smaller the average drop. People with type 2 diabetes and people with established heart disease do not lose weight at the same rate as otherwise-healthier participants with obesity. Our clinical trials overview tracks how each arm of TRIUMPH compares.

Tolerability Rose With the Sicker Populations Too

This is the second signal buried in the topline. A total of 7.7% of TRIUMPH-2 patients discontinued treatment due to adverse events — rising to 11.6% for those on 9 mg — while 13.5% of patients in the 12 mg TRIUMPH-3 cohort discontinued, slightly higher than the 11.3% seen in TRIUMPH-1, a figure analysts had praised at the time as significantly improved.

The adverse events themselves were unsurprising for this drug class: the most common across both trials were diarrhoea, nausea, constipation and decreased appetite. More detail on the safety profile across the programme is in our safety section.

The takeaway isn't alarm — it's that discontinuation rates track with how unwell the trial population is. A regulator reviewing a 2027 filing will read those three numbers side by side, not in isolation.

Why "Topline" Is Doing Heavy Lifting Here

Everything above comes from company press releases and conference reporting, not from a peer-reviewed manuscript. As of now, only one of the phase 3 trials has completed peer review — TRANSCEND-T2D-1, published in The Lancet in June 2026 — while TRIUMPH-1 has been presented at the American Diabetes Association Scientific Sessions but not published in full.

That gap is normal in drug development, but it means the granular data — subgroup breakdowns, adjudicated cardiovascular events, full adverse-event tables — is not yet in the public domain for TRIUMPH-2 or TRIUMPH-3. Anyone drawing firm conclusions about retatrutide's cardiovascular profile today is running ahead of the evidence. Read our primer on how retatrutide works for the mechanism behind why glucagon agonism raises distinct cardiovascular questions in the first place.

The Australian Read

There is a real local implication here, and it's narrow. Retatrutide remains investigational and is not TGA-approved in Australia; Lilly's first regulatory filing is planned for the FDA in Q1 2027. For Australians with obesity and established heart disease — a large overlap in a country where roughly 66.8% of adults are overweight or obese — TRIUMPH-3 confirms the drug was studied in people like them and produced substantial weight loss. It does not yet demonstrate that it prevents cardiac events, which is the kind of evidence that typically carries the most weight in reimbursement arguments anywhere. Our Australia page covers the local regulatory position as it stands.

Want the next readout the day it lands? Join the free updates list.

FAQ

What were the retatrutide TRIUMPH-3 results?

Lilly reported in July 2026 that TRIUMPH-3, which studied adults with obesity and established cardiovascular disease, met its primary endpoint, with reporting citing 22.6% weight loss at the 12 mg dose. These are topline company-reported results, not yet peer-reviewed.

Does retatrutide reduce the risk of heart attack or stroke?

That has not been established. TRIUMPH-3's primary endpoint was percent change in body weight, not cardiovascular events, so the trial was not designed to prove cardiovascular risk reduction.

How much weight did people lose in TRIUMPH-2?

Participants on 12 mg lost 20.8% of body weight at 80 weeks versus 3.2% on placebo. TRIUMPH-2 enrolled adults with obesity or overweight and type 2 diabetes, a population that typically loses less weight than participants without diabetes.

When will retatrutide be submitted for approval?

Lilly has said it plans to submit a Biologics License Application to the US FDA in the first quarter of 2027. No Australian TGA submission has been announced, and retatrutide is not approved anywhere.

Sources

This article is for general information only and is not medical advice. Retatrutide is an investigational medicine and is not approved by the TGA or any other regulator. Speak to a qualified Australian health professional about your own circumstances. retatrutide.net.au is an independent information site and is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.